Featured Story

  • Pfizer's Trumenba shows 'robust' MenB protection in two PhIII trials

    Pfizer's meningitis B vaccine Trumenba won the FDA's blessing nearly a year ago based on impressive midstage results and national unease about the infection spreading on college campuses. Now, the New York-based pharma announced positive late-stage results on Friday in nearly 7,000 individuals that confirmed the vaccine's effectiveness against certain meningits B strains.

Takeda expands vaccine platform rights with Nanotherapeutics agreement

In an effort to widen the reach of its flu vaccines business--and to develop new vaccines on a familiar platform--Takeda has inked an agreement to expand its rights to the Vero cell technology platform for vaccines production from Florida's Nanotherapeutics, Inc.

FluGen reels in $12M to fund PhI of its universal flu jab

A day after two high-profile organizations announced successful animal results for their own universal flu vaccine, Madison, WI-based FluGen announced a $12 million Series A round to fund the development of its candidate in the race.

Valneva licenses EB66 technology to develop human, veterinary vaccines

Valneva has already made 5 deals this year licensing the use of its EB66 cell line to develop new vaccines, and now, it is adding two more to the list.

Mathematical models show one dose of Shanchol may be sufficient during epidemics

Shanchol, the cholera vaccine used in endemic countries, is given in two doses 6 weeks apart. But some patients may simply not return for a second dose. If the second dose is delayed by more than 6 weeks, the WHO says, the whole regimen has to be restarted.

Inovio's MERS vaccine shows 100% protection in mice, camels, monkeys

Since 2012, 1,118 cases of Middle East respiratory syndrome (MERS) have been reported in Saudi Arabia and 483 people have died, but there is no vaccine that might head off an outbreak. Among those working to bring a vaccine to market to prevent such an epidemic is Inovio, which announced on Wednesday that its MERS candidate induced 100% protection from a live virus challenge in mice, camels and monkeys.


From Our Sister Sites


The FDA warned of a Covidien ventilator that may not deliver enough air, and another one from Dräger Medical that has faulty batteries. The ongoing corrective actions of about 2,700 units of the devices have been deemed Class 1, a designation reserved for situations "in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death."


Transmedics' "heart in a box" has been used to preserve at least 15 hearts taken from dead patients in the the U.K. and Australia. The device increases the supply of donated hearts, which stands at about 2,400 per year in the U.S., where the technology is awaiting FDA approval.